Health and wellness company Perrigo Company plc (NYSE; TASE: PRGO) reported on Monday that it has received US Food and Drug Administration tentative approval for the generic version of Finacea Foam(azelaic acid) 15%.
The company added that it had announced a patent litigation suit with Bayer AG for the Finacea Foam (azelaic acid) 15%.
In conjunction with the patent litigation suit, LEO Pharma A/S acquired Finacea Foam (azelaic acid) 15% from Bayer AG and then substituted for Bayer AG as the lead plaintiff in the patent litigation suit concerning the product.
For the 12 months ending January 2019, the annual market sales were approximately USD62m as measured by IQVIA.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT